$REFR
RESEARCH FRONTIERS INC Stock $refr

$refr Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000149315223026617 Filed on August 03, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$164.1K	$185.0K	$85.51K
YoY Change	9.11%	116.39%	-24.95%
Cost Of Revenue	$540.0K	$564.7K	$682.2K
YoY Change	10.77%	-17.23%	35.61%
Gross Profit	-$380.0K	-$379.7K	-$596.7K
YoY Change	12.75%	-36.38%	53.35%
Gross Profit Margin	-231.5%	-205.17%	-697.84%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development	$135.3K	$145.6K	$146.4K
YoY Change	-9.28%	-0.56%	4.74%
% of Gross Profit
Depreciation & Amortization	$10.00K	$6.840K	$14.31K
YoY Change	38.89%	-52.2%	-4.22%
% of Gross Profit
Operating Expenses	$678.0K	$145.6K	$828.7K
YoY Change	6.49%	-82.43%	28.9%
Operating Profit	-$513.8K	-$525.3K	-$743.2K
YoY Change	5.68%	-29.32%	40.5%
Interest Expense	$40.00K	$31.61K	$1.320K
YoY Change	1526.02%	2294.7%	29.41%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$470.0K	-$493.7K	-$741.8K
YoY Change	-2.84%	-33.46%	40.52%
Income Tax
% Of Pretax Income
Net Earnings	-$472.2K	-$493.7K	-$741.8K
YoY Change	-2.39%	-33.46%	40.52%
Net Earnings / Revenue	-287.65%	-266.78%	-867.54%
Basic Earnings Per Share	-$0.01	-$0.01	-$0.02
Diluted Earnings Per Share	-$0.01	-$0.01	-$23.44K
COMMON SHARES
Basic Shares Outstanding	33.51M shares	33.51M shares	31.65M shares
Diluted Shares Outstanding	33.51M shares	33.51M shares	31.65M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.020M	$3.518M	$1.900M
YoY Change	-37.08%	85.14%	-45.27%
Cash & Equivalents	$525.0K	$3.518M	$1.900M
Short-Term Investments	$2.500M	$0.00	$0.00
Other Short-Term Assets	$160.0K	$231.8K	$235.4K
YoY Change	-3.94%	-1.53%	17.72%
Inventory
Prepaid Expenses
Receivables	$721.2K	$666.2K	$442.5K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$3.910M	$4.416M	$2.562M
YoY Change	-28.89%	72.35%	-43.09%
LONG-TERM ASSETS
Property, Plant & Equipment	$46.16K	$303.2K	$79.61K
YoY Change	-36.37%	280.88%	-87.77%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$56.07K	$56.07K	$33.57K
YoY Change	67.03%	67.04%	-0.01%
Total Long-Term Assets	$316.7K	$359.3K	$510.0K
YoY Change	-32.08%	-29.55%	-25.49%
TOTAL ASSETS
Total Short-Term Assets	$3.910M	$4.416M	$2.562M
Total Long-Term Assets	$316.7K	$359.3K	$510.0K
Total Assets	$4.227M	$4.775M	$3.072M
YoY Change	-29.14%	55.43%	-40.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$32.10K	$45.79K	$31.70K
YoY Change	-15.55%	44.46%	-22.84%
Accrued Expenses	$20.57K	$227.3K	$62.08K
YoY Change	-37.56%	266.13%	-73.42%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$264.2K	$285.9K	$291.0K
YoY Change	-1.3%	-1.74%	-3.22%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$110.0K	$163.8K	$367.2K
YoY Change	-65.39%	-55.38%	-34.1%
Total Long-Term Liabilities	$110.0K	$163.8K	$367.2K
YoY Change	-65.39%	-55.38%	-34.1%
TOTAL LIABILITIES
Total Short-Term Liabilities	$264.2K	$285.9K	$291.0K
Total Long-Term Liabilities	$110.0K	$163.8K	$367.2K
Total Liabilities	$374.2K	$449.7K	$658.2K
YoY Change	-36.09%	-31.67%	-23.28%
SHAREHOLDERS EQUITY
Retained Earnings	-$123.8M	-$123.3M	-$121.1M
YoY Change	1.89%	1.82%
Common Stock	$127.6M	$127.6M	$123.5M
YoY Change	0.56%	3.37%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.900M	$4.325M	$2.400M
YoY Change
Total Liabilities & Shareholders Equity	$4.227M	$4.775M	$3.072M
YoY Change	-29.14%	55.43%	-40.76%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$472.2K	-$493.7K	-$741.8K
YoY Change	-2.39%	-33.46%	40.52%
Depreciation, Depletion And Amortization	$10.00K	$6.840K	$14.31K
YoY Change	38.89%	-52.2%	-4.22%
Cash From Operating Activities	-$530.0K	-$625.8K	-$581.8K
YoY Change	-1.08%	7.56%	-21.88%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$600.00	-$460.00
YoY Change	-100.0%	-230.43%	-51.06%
Acquisitions
YoY Change
Other Investing Activities	-$2.470M	$2.992M	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$2.470M	$2.991M	-$460.00
YoY Change	1646566.67%	-650302.17%	-99.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	0.000
YoY Change	-100.0%		-100.0%
NET CHANGE
Cash From Operating Activities	-530.0K	-625.8K	-581.8K
Cash From Investing Activities	-2.470M	2.991M	-460.0
Cash From Financing Activities	0.000	0.000	0.000
Net Change In Cash	-3.000M	2.365M	-582.3K
YoY Change	-202.95%	-506.18%	-85.0%
FREE CASH FLOW
Cash From Operating Activities	-$530.0K	-$625.8K	-$581.8K
Capital Expenditures	$0.00	$600.00	-$460.00
Free Cash Flow	-$530.0K	-$626.4K	-$581.4K
YoY Change	-1.05%	7.75%	-21.84%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0000793524
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue		usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Entity File Number EntityFileNumber	000-14893
	dei	Entity Registrant Name EntityRegistrantName	RESEARCH FRONTIERS INCORPORATED
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	11-2103466
	dei	Entity Address Address Line1 EntityAddressAddressLine1	240 CROSSWAYS PARK DRIVE
	dei	Entity Address City Or Town EntityAddressCityOrTown	WOODBURY
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	11797-2033
	dei	City Area Code CityAreaCode	516
	dei	Local Phone Number LocalPhoneNumber	364-1902
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	REFR
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	33509287	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3517574	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4230916	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1158450	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1158450	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	666157	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	589599	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	231764	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	100973	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	4415495	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	4921488	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	53031	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	65388	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	250201	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	323509	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	56066	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	56066	usd
CY2023Q2	us-gaap	Assets Assets	4774793	usd
CY2022Q4	us-gaap	Assets Assets	5366451	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	203378	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	196405	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	45787	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	71079	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23930	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	34379	usd
CY2023Q2	us-gaap	Deferred Revenue DeferredRevenue	12794	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	285889	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	301863	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	163825	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	267723	usd
CY2023Q2	us-gaap	Liabilities Liabilities	449714	usd
CY2022Q4	us-gaap	Liabilities Liabilities	569586	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33509287	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33509287	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33150396	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33150396	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	3351	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	3315	usd
CY2023Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	127634493	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	127150027	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-123312765	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-122356477	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	4325079	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4796865	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4774793	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5366451	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	433215	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	259339	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	185040	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	85511	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1152493	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1282937	usd
CY2023Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	564694	usd
CY2022Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	682239	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	294832	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	295257	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	145610	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	146432	usd
	us-gaap	Operating Expenses OperatingExpenses	1447325	usd
	us-gaap	Operating Expenses OperatingExpenses	1578194	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	710304	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	828671	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1014110	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1318855	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-525264	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-743160	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	57822	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-51331	usd
CY2023Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	31614	usd
CY2022Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	1322	usd
	us-gaap	Net Income Loss NetIncomeLoss	-956288	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1370186	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-493650	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-741838	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33397968	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33397968	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31650396	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31650396	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33509287	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33509287	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31650396	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31650396	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33397968	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31650396	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33509287	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31650396	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	3783923	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1370186	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	2413737	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4796865	usd
	REFR	Stock Issued During Period Value Stock Warrants Of Exercised StockIssuedDuringPeriodValueStockWarrantsOfExercised	484502	usd
	us-gaap	Net Income Loss NetIncomeLoss	-956288	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	4325079	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	3155575	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-741838	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	2413737	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	4818729	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	4818729	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-493650	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	4325079	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	4325079	usd
	us-gaap	Net Income Loss NetIncomeLoss	-956288	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1370186	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	13661	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	14409	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	26375	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-60143	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	73308	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	73005	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-5000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	156772	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	71558	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-232410	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	130791	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	142424	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-35741	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-22063	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	12794	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	7171	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-96925	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-89016	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1222915	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1079779	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1304	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1067	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	2965160	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2991535	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2694968	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	25071	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2693901	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	484502	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	484502	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-713342	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1614122	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4230916	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	269964	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3517574	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1884086	usd
	us-gaap	Basis Of Accounting BasisOfAccounting	<p id="xdx_80E_eus-gaap--BasisOfAccounting_zM3eK1SaHt92" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Note 1. <span id="xdx_82F_zUGq4LfQymZe">Basis of Presentation</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of a normal recurring nature. Operating results for the three and six months ended June 30, 2023 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2023. The condensed consolidated balance sheet at December 31, 2022 has been derived from the audited consolidated financial statements at that date. For further information, refer to the consolidated financial statements and footnotes thereto included in the Annual Report on Form 10-K relating to Research Frontiers Incorporated for the fiscal year ended December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_806_eus-gaap--NatureOfOperations_zgMponXgeIu3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Note 2. <span id="xdx_821_zpnWe6xdigWe">Business</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research Frontiers Incorporated (“Research Frontiers” or the “Company”) operates in a single business segment which is engaged in the development and marketing of technology and devices to control the flow of light. Such devices, often referred to as “light valves” or suspended particle devices (“SPDs”), use colloidal particles that are either incorporated within a liquid suspension or a film, which is usually enclosed between two sheets of glass or plastic having transparent, electrically conductive coatings on the facing surfaces thereof. At least one of the two sheets is transparent. SPD technology, made possible by a flexible light-control film invented by Research Frontiers, allows the user to instantly and precisely control the shading of glass/plastic manually or automatically. SPD technology has numerous product applications, including SPD-Smart™ windows, sunshades, skylights and interior partitions for homes and buildings; automotive windows, sunroofs, sun visors, sunshades, rear-view mirrors, instrument panels and navigation systems; aircraft windows; museum display panels; eyewear products; and flat panel displays for electronic products. SPD-Smart light control film is now being developed for, or used in, architectural, automotive, marine, aerospace and appliance applications.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has primarily utilized its cash, cash equivalents, and investments generated from sales of our common stock, proceeds from the exercise of options and warrants, and royalty fees collected to fund its research and development of SPD light valves, for marketing initiatives, and for other working capital purposes. The Company’s working capital and capital requirements depend upon numerous factors, including the results of research and development activities, competitive and technological developments, the timing and cost of patent filings, and the development of new licensees and changes in the Company’s relationships with its existing licensees. The degree of dependence of the Company’s working capital requirements on each of the foregoing factors cannot be quantified; increased research and development activities and related costs would increase such requirements; the addition of new licensees may provide additional working capital or working capital requirements; and changes in relationships with existing licensees would have a favorable or negative impact depending upon the nature of such changes. We have incurred recurring losses since inception and expect to continue to incur losses as a result of costs and expenses related to our research and continued development of our SPD technology and our corporate general and administrative expenses. Our capital requirements and operations to date have been substantially funded through sales of our common stock, exercise of options and warrants and royalty fees collected. As of June 30, 2023, we had working capital of approximately $<span id="xdx_909_ecustom--WorkingCapital_iI_pn5n6_c20230630_zYZck9ffLaD7" title="Working capital">4.1</span> million, cash and cash equivalents of approximately $<span id="xdx_900_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20230630_zGJD3N80zUL6" title="Cash and cash equivalents and marketable securities">3.5</span> million, shareholders’ equity of approximately $<span id="xdx_903_eus-gaap--StockholdersEquity_iI_pn5n6_c20230630_zaPjilXGFPpe" title="Shareholders' equity">4.3</span> million and an accumulated deficit of approximately $<span id="xdx_906_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20230630_zyRx5y94uVm5" title="Accumulated deficit">123.3</span> million. Our projected cash flow shortfall based on our current operations adjusted for any non-recurring cash expenses and adjusted for additional royalties expected to be received for use of our products in new production for the next 12 months is approximately $<span id="xdx_901_ecustom--NonrecurringCashExpenses_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_zYw7fnXJxJW2" title="Non-recurring cash expenses">200,000</span> to $<span id="xdx_904_ecustom--NonrecurringCashExpenses_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_zwxXawX5Ns49" title="Non-recurring cash expenses">250,000</span> per quarter. Based on our current expectations of our cash flow shortfall for the next 12 months, our working capital would support our activities for at least the next 12 months from the issuance of these condensed consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the event that we are unable to generate sufficient cash from our operating activities or raise additional funds, we may be required to delay, reduce or severely curtail our operations or otherwise impede our on-going business efforts, which could have a material adverse effect on our business, operating results, financial condition and long-term prospects. The Company may seek to obtain additional funding through future equity issuances. There can be no assurance as to the availability or terms upon which such financing and capital might be available. The eventual success of the Company and generation of positive cash flow will be dependent upon the commercialization of products using the Company’s technology by the Company’s licensees and payments of continuing royalties on account thereof. To date, the Company has not generated sufficient revenue from its licensees to fund its operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2	REFR	Working Capital WorkingCapital	4100000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3500000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	4300000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-123300000	usd
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2541100	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1234887	shares
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M18D
CY2023Q2	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	125000	usd
CY2022Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2000000.0	shares
CY2022Q3	us-gaap	Common Stock Convertible Conversion Price Increase CommonStockConvertibleConversionPriceIncrease	2.30
CY2022Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	3450000	usd
CY2022Q3	REFR	Proceeds From Expects To Receive Remaining Amount ProceedsFromExpectsToReceiveRemainingAmount	1150000	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.055	pure
CY2023Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	55000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	109000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	108000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	222000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	56000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	386000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	18797	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	367203	usd
CY2023Q2	us-gaap	Marketable Securities MarketableSecurities	0	usd
CY2022Q2	us-gaap	Marketable Securities MarketableSecurities	0	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	26375	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-60143	usd

Files In Submission

Name	View Source	Status
0001493152-23-026617-index-headers.html	Edgar Link	pending
0001493152-23-026617-index.html	Edgar Link	pending
0001493152-23-026617.txt	Edgar Link	pending
0001493152-23-026617-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
refr-20230630.xsd	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
refr-20230630_cal.xml	Edgar Link	unprocessable
refr-20230630_def.xml	Edgar Link	unprocessable
refr-20230630_lab.xml	Edgar Link	unprocessable
refr-20230630_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$REFR
RESEARCH FRONTIERS INC Stock $refr

2023 Q3 Form 10-Q Financial Statement

#000149315223026617 Filed on August 03, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REFR RESEARCH FRONTIERS INC Stock $refr

2023 Q3 Form 10-Q Financial Statement

#000149315223026617 Filed on August 03, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REFR
RESEARCH FRONTIERS INC Stock $refr